Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leela Barham

Latest From Leela Barham

Bluebird Bio Decision in Europe Is A Wake-Up Call For Payers and Industry

Bluebird bio’s decision to focus on the US market is being seen as a broader signal of the need for changes in market access policies to enable gene therapies to be made available for European patients. Only collaborative work will create solutions acceptable to payers and companies, and finding an acceptable price that both can live with will be crucial.

Europe Reimbursement

Flexibility Is Key To Making England’s Innovative Medicines Fund Work

Stakeholders are calling for NHS England and NHS Improvement (NHSE&I) and the health technology assessment body NICE to bring more flexibility into England’s new Innovative Medicines Fund, which is due for launch later in 2021.

United Kingdom Government Payers

Expectations Are High But What Precisely Will England’s New IMF Deliver?

The Innovative Medicines Fund, due for launch in England later this year, may provide industry with an opportunity to hold key public bodies to account.

United Kingdom Market Access

Make It Better And Put More Money In – Industry On England’s New Innovative Medicines Fund

While they await further details on England’s new Innovative Medicines Fund, industry and other stakeholders are asking questions about how far the fund – due for launch later this year – will be adapted to fit non-cancer therapies.

Reimbursement United Kingdom

UK Branded Medicines Pricing & Access Deal - Hits & Misses To Date

Industry has paid millions of pounds under the ongoing UK Voluntary Scheme on Branded Medicines Pricing and Access but there are concerns over poor progress with other commitments that were promised under the scheme for managing branded medicine spend by the National Health Service.

United Kingdom Market Access

Could Reformed HTA Be A Legacy Of COVID-19?

The COVID-19 pandemic will have a lasting impact on the world, including on Health Technology Assessment (HTA). The debate on how HTA should change as a result of COVID-19 is gaining momentum, but could a wider approach to value and a higher threshold be a false dawn?

Coronavirus COVID-19 Health Technology Assessment
See All
UsernamePublicRestriction

Register